OS, PFS, Quality of Life
Conditions
Keywords
neoadjuvant chemotherapy, radical surgery, cervical carcinoma
Brief summary
To clarify the potential benefits of NACT before radical surgery(RS), we perform a phase III, randomised controlled trial to compare NACT plus RS with RS alone in patients with stages IB2 and IIA2 cervical cancer.
Detailed description
Patients with International Federation of Gynecology and Obstetrics (FIGO) stage IB2 and IIA2 cervical cancer are eligible for our study. They will receive paclitaxel + cisplatin(TP)/carboplatin(TC) regimen neoadjuvant chemotherapy (NACT) 3 cycles followed by radical surgery (RS) (type III to V radical hysterectomy plus systematic pelvic lymphadenectomy) (arm A) or directly radical surgery (arm B). Postoperative pelvic radiotherapy will be started within 6 weeks after surgery if the patients have pelvic lymph node metastasis, parametrial involvement, deep stromal invasion or positive margin. Extended-field external beam therapy, delivering a dose of 4500cGy by a four-field technique, will be administered to patients with positive para-aortic nodes. High-dose rate brachytherapy will be delivered to the vaginal stump if patients have positive surgical margins. The primary end point is 2-years progression-free survival, The secondary end points is overall survival , rate of response to TP or TC regimen chemotherapy and the quality of life.
Interventions
DRUGNACT (Paclitaxel + Cisplatin or carboplatin)
Paclitaxel 150mg/m2 over 3 hours + Cisplatin 70mg/m2 or carboplatin AUC = 6, repeat per 21 days, 3 cycles.
PROCEDUREradical surgery
Radical hysterectomy (Piver Type III or Type IV hysterectomy) plus bilateral pelvic lymph node dissection and para-aortic lymph node dissection or sampling
Sponsors
Sun Yat-sen University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Patients with newly histologically confirmed cervical carcinoma; * Histopathology squamaous carcinoma, adenocarcinoma or adeno-squamous carcinoma; * Original clinical stage must be IB2 or IIA2 （FIGO); * Age between 18-65; * Patients must give signed informed consent; * P.S status: 0-1; * Estimated survival time \> 3 months;
Exclusion criteria
* The presence of uncontrolled life-threatening illness; * Receiving other ways of anti-cancer therapy; * Investigator consider the patients can't finish the whole study; * With normal liver function test (ALT、AST\>2.5×ULN); * With normal renal function test (Creatinine\>1.5×ULN); * WBC\<4,000/mm3 or PLT\<100,000/mm; * Accompany with other malignancy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease free survival | 2 years |
Secondary
| Measure | Time frame |
|---|---|
| overall survival | 5 years |
| quality of life | 3 years |
Countries
China
Contacts
Primary ContactJihong Liu, Ph. D
Backup ContactTing Wan, Ph. D
Outcome results
None listed